CN Patent

CN106146506A — (s)‑2‑(1‑(9h‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3h)‑酮的多晶型物

Assigned to Gilead Calistoga LLC · Expires 2016-11-23 · 9y expired

What this patent protects

本申请公开了(S)‑2‑(1‑(9H‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3H)‑酮的多晶型物、其组合物、其制备方法及其使用方法。

USPTO Abstract

本申请公开了(S)‑2‑(1‑(9H‑嘌呤‑6‑基氨基)丙基)‑5‑氟‑3‑苯基喹唑啉‑4(3H)‑酮的多晶型物、其组合物、其制备方法及其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN106146506A
Jurisdiction: CN
Classification: —
Expires: 2016-11-23
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Calistoga LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.